Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.65% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.47M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 41132 | Beta -1.64 | 52 Weeks Range 1.15 - 3.45 | Updated Date 04/1/2025 |
52 Weeks Range 1.15 - 3.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.79% | Operating Margin (TTM) -2.33% |
Management Effectiveness
Return on Assets (TTM) -2.51% | Return on Equity (TTM) -22.74% |
Valuation
Trailing PE - | Forward PE 0.88 | Enterprise Value 2857817 | Price to Sales(TTM) 0.1 |
Enterprise Value 2857817 | Price to Sales(TTM) 0.1 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 0.53 | Shares Outstanding 6169850 | Shares Floating 4493685 |
Shares Outstanding 6169850 | Shares Floating 4493685 | ||
Percent Insiders 2.69 | Percent Institutions 30.53 |
Analyst Ratings
Rating 4 | Target Price 8 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience Inc., now known as Validus Ventures, was founded in 2002 as Rosewind Corporation and later changed its name to Aytu BioScience Inc. in 2015. It focused on commercializing novel products in the fields of urology, pediatrics, and consumer health. Significant milestones included acquiring various product lines and companies to expand its portfolio. The company's evolution involved shifting its focus through acquisitions and strategic partnerships.
Core Business Areas
- Urology: Focused on commercializing and marketing prescription products for urological conditions.
- Consumer Health: Offers over-the-counter consumer health products, particularly in the areas of cough, cold and allergy.
Leadership and Structure
The company's leadership team consists of key executives with experience in pharmaceuticals, healthcare, and finance. The organizational structure includes departments for sales, marketing, research and development, and operations. As of now, the current leadership is headed by Josh Disbrow as CEO and Jarrod Moses as CFO.
Top Products and Market Share
Key Offerings
- Natesto: Natesto is a nasal testosterone gel for treating hypogonadism in men. Market share information is difficult to determine exactly due to variability in reporting. Competition includes injectable testosterone, topical gels (Androgel), and testosterone patches. Sales of Natesto were $2.5 million in 2022.
- Poly-Vi-Sol: Poly-Vi-Sol is a multivitamin supplement for infants and children. Market data is limited in specific terms, but Mead Johnson and Pedia-Vite are major competitors in the market.
- Aciphex: AcipHex sprinkle for acid reflux in infants and children. The company acquired this product in 2022. Takeda's Dexilant and other brands are major competitors. Sales of AcipHex were $0.9 million in 2022.
Market Dynamics
Industry Overview
The pharmaceutical and consumer health industries are characterized by intense competition, evolving regulatory landscapes, and increasing demand for innovative products and cost-effective solutions.
Positioning
Aytu BioScience Inc's position is primarily as a specialty pharmaceutical company focused on niche markets and commercializing products in urology, pediatrics, and consumer health. Its competitive advantage lies in its targeted product portfolio and strategic partnerships.
Total Addressable Market (TAM)
The TAM for the company's products spans across urology, pediatrics, and general consumer health, potentially reaching billions of dollars globally. Aytu BioScience Inc is positioned to capture a portion of this market through targeted sales and marketing efforts, as well as new product launches.
Upturn SWOT Analysis
Strengths
- Strategic acquisitions
- Diverse product portfolio
- Experienced leadership team
- Partnerships and collaborations
- Focus on niche markets
Weaknesses
- Limited financial resources
- Dependence on key products
- Small market capitalization
- Fluctuations in sales
- History of net losses
Opportunities
- Expanding product line through acquisitions
- Entering new geographic markets
- Developing innovative products
- Partnering with larger pharmaceutical companies
- Capitalizing on unmet medical needs
Threats
- Intense competition
- Regulatory changes
- Patent expirations
- Product recalls
- Economic downturn
Competitors and Market Share
Key Competitors
- Endo International (ENDP)
- Pfizer (PFE)
- Bayer (BAYRY)
Competitive Landscape
Aytu BioScience Inc faces intense competition from larger pharmaceutical companies with greater resources and established market positions. Its competitive advantage lies in its targeted product portfolio and strategic partnerships.
Major Acquisitions
Cenegenics
- Year: 2020
- Acquisition Price (USD millions): 47.2
- Strategic Rationale: Expanding into preventative healthcare and age management sectors, which can be complementary to its existing product lines. This acquisition helped boost the company revenues.
Growth Trajectory and Initiatives
Historical Growth: Aytu BioScience Inc's historical growth has been characterized by periods of expansion through acquisitions followed by periods of consolidation and restructuring.
Future Projections: Future growth projections are dependent on successful commercialization of existing products and new acquisitions. Analyst estimates vary widely based on the company's ability to execute its business plan.
Recent Initiatives: Recent strategic initiatives include restructuring the company's debt, focusing on core product lines, and exploring new partnerships and acquisitions.
Summary
Aytu BioScience Inc has shown rapid growth through acquisitions, but faces challenges due to limited resources and intense competition. Strategic acquisitions and product diversification are strengths, while dependence on key products and financial constraints are weaknesses. The company needs to focus on financial stability and effective commercialization of its products to improve its market position.
Similar Companies
- PFE
- BAYRY
- VRX
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Third-party financial data providers (Yahoo Finance, Google Finance)
- Company press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 102 | Website https://aytubio.com |
Full time employees 102 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.